Keun Chan Park

Founder at Theromics, Inc.

Health Technology

Profile

William Keun Chan Park is the founder of Theromics, Inc. He held the title of Chief Science Officer at the company, and his job functions included FOU (Founder) and CTO (Chief Technology Officer).

Keun Chan Park active positions

Companies	Position	Start
Theromics, Inc. Theromics, Inc. Medical SpecialtiesHealth Technology Theromics, Inc. is a medical device technology company that is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The company is based in West Bridgewater, MA. The company's proprietary heatsync™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. The company was founded by Damian E. Dupuy, William Keun Chan Park. The CEO is Ron Murphy.	Founder	-

All active positions of Keun Chan Park

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Keun Chan Park's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Theromics, Inc. Theromics, Inc. Medical SpecialtiesHealth Technology Theromics, Inc. is a medical device technology company that is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The company is based in West Bridgewater, MA. The company's proprietary heatsync™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. The company was founded by Damian E. Dupuy, William Keun Chan Park. The CEO is Ron Murphy.	Health Technology